PepGen Inc. (PEPG)
NASDAQ: PEPG
· Real-Time Price · USD
1.41
-0.08 (-5.37%)
At close: Jun 17, 2025, 2:07 PM
Company Description
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases.
The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD).
It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD.
The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
PepGen Inc.

Country | United States |
IPO Date | May 6, 2022 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 79 |
CEO | Dr. James G. McArthur Ph.D. |
Contact Details
Address: 245 Main Street Boston, Massachusetts United States | |
Website | https://www.pepgen.com |
Stock Details
Ticker Symbol | PEPG |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001835597 |
CUSIP Number | 713317105 |
ISIN Number | US7133171055 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. James G. McArthur Ph.D. | President, Chief Executive Officer, Treasurer, Secretary & Director |
Noel P. Donnelly M.B.A. | Chief Financial Officer |
Dr. Afsaneh Mohebbi Ph.D. | Senior Vice President of Portfolio and Program Management |
Dr. Hayley Parker Ph.D. | Senior Vice President of Global Regulatory Affairs |
Dr. Michael Gait Ph.D. | Founder & Scientific Advisory Board Member |
Dr. Paul D. Streck M.B.A., M.D. | Executive Vice President and Head of Research & Development |
Emiko Bryant | Chief of Staff, HR & Operations |
Kyle Breidenstine CPA, M.B.A. | Vice President of Finance & Controller |
Mary Beth DeLena J.D. | General Counsel & Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 06, 2025 | 4 | Filing |
Jun 06, 2025 | 8-K | Current Report |
Jun 06, 2025 | 4 | Filing |
Jun 06, 2025 | 4 | Filing |
Jun 06, 2025 | 4 | Filing |
Jun 06, 2025 | 4 | Filing |
Jun 06, 2025 | 4 | Filing |
Jun 02, 2025 | 4 | Filing |
May 28, 2025 | 8-K | Current Report |
May 21, 2025 | 4 | Filing |